A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

1/24/2024, 10:15 PM

This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe and effective for women seeking abortions.

Bill 118 sres 510 is a resolution introduced in the US Senate that aims to express the Senate's support for the scientific judgement of the Food and Drug Administration (FDA) regarding the safety and effectiveness of mifepristone, a medication used for medication abortion. The resolution emphasizes the importance of respecting the FDA's expertise and decisions in determining the safety and efficacy of medications.

Additionally, the resolution calls for laws and policies governing access to medication abortion care in the United States to be equitable and based on scientific evidence. It highlights the importance of ensuring that individuals have timely access to lifesaving medication abortion care, and that restrictions on access to this care should be based on scientific evidence rather than political ideology.

Overall, Bill 118 sres 510 seeks to promote a fair and science-based approach to regulating access to medication abortion care in the United States, emphasizing the importance of respecting the FDA's scientific judgement and ensuring equitable access to this important healthcare service.
Congress
118

Number
SRES - 510

Introduced on
2023-12-14

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

12/14/2023

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe and effective for women seeking abortions.

Bill 118 sres 510 is a resolution introduced in the US Senate that aims to express the Senate's support for the scientific judgement of the Food and Drug Administration (FDA) regarding the safety and effectiveness of mifepristone, a medication used for medication abortion. The resolution emphasizes the importance of respecting the FDA's expertise and decisions in determining the safety and efficacy of medications.

Additionally, the resolution calls for laws and policies governing access to medication abortion care in the United States to be equitable and based on scientific evidence. It highlights the importance of ensuring that individuals have timely access to lifesaving medication abortion care, and that restrictions on access to this care should be based on scientific evidence rather than political ideology.

Overall, Bill 118 sres 510 seeks to promote a fair and science-based approach to regulating access to medication abortion care in the United States, emphasizing the importance of respecting the FDA's scientific judgement and ensuring equitable access to this important healthcare service.
Alternative Names
Official Title as IntroducedA resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

Policy Areas
Health

Comments

Recent Activity

Latest Summary12/19/2024

This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe...


Latest Action12/14/2023
Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S6003-6004)